GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » EV-to-EBITDA

Carna Biosciences (TSE:4572) EV-to-EBITDA : -3.58 (As of May. 26, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Carna Biosciences's enterprise value is 円3,613 Mil. Carna Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was 円-1,011 Mil. Therefore, Carna Biosciences's EV-to-EBITDA for today is -3.58.

The historical rank and industry rank for Carna Biosciences's EV-to-EBITDA or its related term are showing as below:

TSE:4572' s EV-to-EBITDA Range Over the Past 10 Years
Min: -88.84   Med: -11.36   Max: 335.25
Current: -3.58

During the past 13 years, the highest EV-to-EBITDA of Carna Biosciences was 335.25. The lowest was -88.84. And the median was -11.36.

TSE:4572's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.67 vs TSE:4572: -3.58

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Carna Biosciences's stock price is 円388.00. Carna Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was 円-60.293. Therefore, Carna Biosciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Carna Biosciences EV-to-EBITDA Historical Data

The historical data trend for Carna Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carna Biosciences EV-to-EBITDA Chart

Carna Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.08 -10.31 -22.35 -3.36 -5.72

Carna Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.33 -4.77 -5.29 -5.72 -5.17

Competitive Comparison of Carna Biosciences's EV-to-EBITDA

For the Biotechnology subindustry, Carna Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's EV-to-EBITDA falls into.



Carna Biosciences EV-to-EBITDA Calculation

Carna Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3613.285/-1010.64
=-3.58

Carna Biosciences's current Enterprise Value is 円3,613 Mil.
Carna Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,011 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Carna Biosciences  (TSE:4572) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Carna Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=388.00/-60.293
=At Loss

Carna Biosciences's share price for today is 円388.00.
Carna Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-60.293.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Carna Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Carna Biosciences (TSE:4572) Business Description

Traded in Other Exchanges
N/A
Address
BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Carna Biosciences (TSE:4572) Headlines

No Headlines